Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis.

colorectal cancer gut microbiome microbial DNA fragments microbial dysbiosis prognostic markers

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 May 2024
Historique:
received: 31 03 2024
revised: 15 05 2024
accepted: 17 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Colorectal cancer (CRC) significantly contributes to cancer-related mortality, necessitating the exploration of prognostic factors beyond TNM staging. This study investigates the composition of the gut microbiome and microbial DNA fragments in stage II/III CRC. A cohort of 142 patients with stage II/III CRC and 91 healthy controls underwent comprehensive microbiome analysis. Fecal samples were collected for Patients with CRC exhibited distinct microbial composition compared to controls. Beta diversity analysis confirmed CRC-specific microbial profiles. Taxonomic profiling revealed unique taxonomies in the patient cohort. De novo clustering separated individuals into distinct groups, with specific microbial DNA fragment detection associated with certain patient clusters. The gut microbiota can differentiate patients with CRC from healthy individuals. Detecting microbial DNA fragments in the bloodstream may be linked to CRC prognosis. These findings suggest that the gut microbiome could serve as a prognostic factor in stage II/III CRC. Identifying specific microbial markers associated with CRC prognosis has potential clinical implications, including personalized treatment strategies and reduced healthcare costs. Further research is needed to validate these findings and uncover underlying mechanisms.

Sections du résumé

BACKGROUND BACKGROUND
Colorectal cancer (CRC) significantly contributes to cancer-related mortality, necessitating the exploration of prognostic factors beyond TNM staging. This study investigates the composition of the gut microbiome and microbial DNA fragments in stage II/III CRC.
METHODS METHODS
A cohort of 142 patients with stage II/III CRC and 91 healthy controls underwent comprehensive microbiome analysis. Fecal samples were collected for
RESULTS RESULTS
Patients with CRC exhibited distinct microbial composition compared to controls. Beta diversity analysis confirmed CRC-specific microbial profiles. Taxonomic profiling revealed unique taxonomies in the patient cohort. De novo clustering separated individuals into distinct groups, with specific microbial DNA fragment detection associated with certain patient clusters.
CONCLUSIONS CONCLUSIONS
The gut microbiota can differentiate patients with CRC from healthy individuals. Detecting microbial DNA fragments in the bloodstream may be linked to CRC prognosis. These findings suggest that the gut microbiome could serve as a prognostic factor in stage II/III CRC. Identifying specific microbial markers associated with CRC prognosis has potential clinical implications, including personalized treatment strategies and reduced healthcare costs. Further research is needed to validate these findings and uncover underlying mechanisms.

Identifiants

pubmed: 38792001
pii: cancers16101923
doi: 10.3390/cancers16101923
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Hellenic Foundation for Research and Innovation
ID : 17447/10 October 2019
Organisme : Hellenic Society of Medical Oncology
ID : N/A
Organisme : Gastrointestinal Cancer Study Group
ID : N/A
Organisme : European Society for Medical Oncology
ID : N/A

Auteurs

Ippokratis Messaritakis (I)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Andreas Koulouris (A)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Eleni Boukla (E)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Konstantinos Vogiatzoglou (K)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Ilias Lagkouvardos (I)

Department of Clinical Microbiology, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Evangelia Intze (E)

Department of Clinical Microbiology, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Maria Sfakianaki (M)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Maria Chondrozoumaki (M)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Michaela Karagianni (M)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.

Elias Athanasakis (E)

Department of General Surgery, Heraklion University Hospital, 71100 Heraklion, Greece.

Evangelos Xynos (E)

Department of Surgery, Creta Interclinic Hospital of Heraklion, 71305 Heraklion, Greece.

John Tsiaoussis (J)

Department of Anatomy, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Manousos Christodoulakis (M)

Department of General Surgery, Venizeleio General Hospital, 71409 Heraklion, Greece.

Matthaios E Flamourakis (ME)

Department of General Surgery, Venizeleio General Hospital, 71409 Heraklion, Greece.

Eleni S Tsagkataki (ES)

Department of General Surgery, Venizeleio General Hospital, 71409 Heraklion, Greece.

Linda Giannikaki (L)

Histopathology, Venizeleio General Hospital, 71409 Heraklion, Greece.

Evdoxia Chliara (E)

Histopathology, Venizeleio General Hospital, 71409 Heraklion, Greece.

Dimitrios Mavroudis (D)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Department of Medical Oncology, University Hospital of Heraklion, 71110 Heraklion, Greece.

Maria Tzardi (M)

Laboratory of Pathology, University General Hospital of Heraklion, 70013 Heraklion, Greece.

John Souglakos (J)

Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Department of Medical Oncology, University Hospital of Heraklion, 71110 Heraklion, Greece.

Classifications MeSH